Core Viewpoint - The Hunan Provincial Medical Insurance Bureau has issued the "Hunan Province Urban and Rural Residents Hypertension and Diabetes Outpatient Medication Scope and Medical Insurance Payment Standards (2026 Edition)", aiming to optimize the outpatient medication guarantee policy for hypertension and diabetes, thereby reducing the medication burden on insured patients and ensuring their medication needs are met [1]. Group 1: Medication Scope Expansion - The policy adjustment is based on the 2025 version of the outpatient medication scope and payment standards for hypertension and diabetes, aligning with the National Basic Medical Insurance Drug Directory (2025) [2]. - All key medications for hypertension and diabetes have been included in the outpatient medication scope, expanding the medication options available to insured patients [2]. Group 2: Dynamic Adjustment of Payment Standards - The Hunan Province has recalculated and determined the payment standards for hypertension and diabetes medications in accordance with national regulations, based on the prices of selected drugs from national negotiations and centralized procurement [3]. - The payment standards will be uniformly established based on the actual procurement situation of relevant drugs in Hunan Province, ensuring compliance with national definitions for treatment payments [3]. Group 3: Information Management and Future Adjustments - Medications selected through national or provincial centralized procurement will be marked with an asterisk for easy identification and management [4]. - The Hunan Provincial Medical Insurance Bureau will maintain a unified information system and prohibit local adjustments to the medication scope and payment standards, with future adjustments to be made dynamically based on updates to the drug directory [4].

Core Viewpoint - The article highlights significant announcements in the stock market from Sunday to Thursday, focusing on various corporate actions such as suspensions, share buybacks, investment wins, acquisitions, earnings reports, and stock unlocks, aiming to help investors identify potential investment opportunities and risks in advance [1] Group 1 - The company has formed a strategic partnership with Zhiyuan Robotics and has secured hardware orders from domestic and international humanoid robot clients [1] - The company is developing six innovative drugs, including those for hypertension [1] - The company has entered the supply chain of leading humanoid robot manufacturers, engaging in sectors such as controllable nuclear fusion, low-altitude economy, and new energy vehicles [1]